Clinical Trial Update: Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer [Phase 1]

View source ↗

Summary

The trial to determine the optimal Phase II dose of an oral dual CAIX inhibitor/radiosensitizer for solid tumors, including head and neck cancers, has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Dual CAIX inhibitor / radiosensitizer (CAIX inhibitor and radiosensitizer)

Snippet

Sponsor: Maastricht Radiation Oncology | Conditions: Solid Tumors, Head and Neck Neoplasms | Phase 1 | Status: WITHDRAWN